Osama Nady Mohamed Mohamed

Dr. Osama Nady Mohamed Mohamed

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Lipid and Atherosclerosis
Verified
Journal Article
Open access
PDF file
OMOsama Nady Mohamed Mohamed
Osama Nady Mohamed Mohamed
MMMahmoud Ragab Mohamed Mohamed
Mahmoud Ragab Mohamed Mohamed
IHIsraa Gamal Hassan
Israa Gamal Hassan
AAAtef Farouk Alakkad
Atef Farouk Alakkad
AOAshraf Othman
Ashraf Othman
AIAhmed S. Issa
Ahmed S. Issa
Mohamed ON, et al. J Lipid Atheroscler. 2024 May;13(2):194-211. https://doi.org/10.12997/jla.2024.13.2.194

18 March 2024 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
OMOsama Nady Mohamed Mohamed
Osama Nady Mohamed Mohamed
SISharehan Abdelrahman Ibrahim
Sharehan Abdelrahman Ibrahim
Rabeh Khairy SalehRabeh Khairy Saleh
Rabeh Khairy Saleh
AIAhmed S. Issa
Ahmed S. Issa
ASAmr Setouhi
Amr Setouhi
SKShaimaa F. Kamel
Shaimaa F. Kamel
Background: Globally, there are regional and time-based variations in the prevalence, etiology, and prognosis of rapidly progressive glomerulonephritis (RPGN). Prognosis of RPGN is poor, with a higher risk of death and end stage renal disease (ESRD) even with immunosuppressive medications. In the Middle East and North Africa, the studies on this disease are very limited. Therefore, we determined the predictors of outcome of RPGN. Methods: We retrospectively assessed 101 adult patients over age of 18, diagnosed with RPGN based on renal biopsy illustrating crescents in ≥ 50% of the glomeruli. Patients who had crescents in their renal biopsies that were < 50% and those who refused to consent to a renal biopsy were excluded. We categorized the patients into 3 groups based on immunohistochemistry; type I, type II and type III. Then, depending on renal loss, we divided them into ESRD and non-ESRD groups. The clinical history and physical examination were retrieved. Additionally, 24-hour urine protein, urine analysis, renal function tests, serum albumin, complete blood count, antinuclear antibodies, anti-double stranded DNA antibodies, ANCA antibodies and serum complement levels were checked. Each patient underwent a kidney biopsy for immunohistochemistry and light microscopy. The percentage of crescentic glomeruli, number of sclerosed glomeruli, tertiary lymphoid organ (TLO), neutrophil infiltration, endocapillary or mesangial hypercellularity, interstitial fibrosis with tubular atrophy (IFTA) were analyzed. Primary outcomes (remission, ESRD and mortality) and secondary outcomes were assessed. Results: Type II was the most frequent cause of RPGN (47.5%), followed by type III (32.7%) and type I (19.8%). 32 patients (31.7%) died during follow up, whereas 60 patients (59.4%) developed ESRD. In 41 patients (40.6%), remission occurred. Oliguria, serum creatinine, and need for HD at presentation were significantly increased in ESRD group compared to non-ESRD group (P < 0.001 for each). Mesangial proliferation, IFTA, TLO formation, sclerotic glomeruli and fibrous crescents were also significantly increased in ESRD group in comparison to non-ESRD group (P < 0.001 for each). Glomerulosclerosis (P = 0.036), and IFTA (P = 0.008) were predictors of ESRD. Infections (P = 0.02), respiratory failure (P < 0.001), and heart failure (P = 0.004) were mortality risk factors. Conclusion: Type II RPGN was the most common. Infection was the most frequent secondary outcome. Oliguria, glomerulosclerosis, the requirement for hemodialysis at presentation, IFTA and TLO formation were predictors of ESRD. Respiratory failure, heart failure and infections were significant predictors of mortality.

10 April 2025 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
OMOsama Nady Mohamed Mohamed
Osama Nady Mohamed Mohamed
MMMarwa Ibrahim Mohamed
Marwa Ibrahim Mohamed
SKShaimaa F. Kamel
Shaimaa F. Kamel
ADAhmed M. Dardeer
Ahmed M. Dardeer
SSSayed Shehata
Sayed Shehata
SEShereen Mohammed Mohammed Elsaghir
Shereen Mohammed Mohammed Elsaghir
Background: There are no studies investigating the role of midkine (MK) in vascular calcification (VC) or vascular disease associated with chronic kidney disease (CKD). This study assessed serum MK level and investigated its relationship with carotid atherosclerosis and coronary artery calcification (CAC) in non-dialysis CKD. Methods: The study comprised 80 controls and 185 adult patients with CKD at stages 3–5 who were free of cardiovascular diseases. Acute renal failure, chronic hemodialysis, severe liver disease, inflammatory states, anticoagulation therapy and cancer were excluded. The patients were classified based on presence of CAC score into severe and mild to moderate CAC groups. They were also divided into atherosclerotic and non-atherosclerotic groups based on carotid atherosclerosis. CBC, kidney function tests, lipid profile, intact parathyroid hormone (iPTH), and phosphorus were assessed. Serum levels of MK, tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) were quantitatively tested using ELISA. Cardiac CT scan was done to calculate CAC score. Carotid ultrasonography was used to evaluate carotid intima media thickness (CIMT) and identify plaques. Results: All CKD categories, including CKD-3, CKD-4, and CKD-5, showed higher rates of carotid plaques (p = 0.007, p < 0.001, and p < 0.001, respectively), higher levels of MK (p < 0.001 for each), and higher CAC scores (p < 0.001 for each) as CKD worsened. Compared to mild to moderate CAC patients, severe CAC patients showed increased CIMT (p < 0.001) and raised serum levels of MK (p < 0.001), TNF-α (p = 0.001), IL-6 (p = 0.002), hs-CRP (p = 0.003), iPTH (p = 0.02), phosphorus (p < 0.001), total cholesterol (TC), and low density lipoprotein-cholesterol (LDL-C). Multivariate linear regression revealed that CAC was reliably predicted by MK (p = 0.008) and serum creatinine (p = 0.001). Carotid atherosclerotic patients had higher serum levels of MK, TNF-α, IL-6, hs-CRP, iPTH, phosphorus, TC, total triglycerides and LDL-C (p < 0.001 for each). Multivariate logistic regression showed that serum MK (p = 0.001), serum creatinine (p = 0.005), age (p < 0.001), iPTH (p = 0.007), and IL-6 (p = 0.024) were significant predictors of carotid atherosclerosis. Conclusions: As CKD worsened, MK levels, carotid atherosclerosis and CAC increased. Serum MK was a reliable biomarker for asymptomatic carotid atherosclerosis and CAC in non-dialysis CKD, allowing prompt early diagnosis to avert cardiovascular morbidity and death in the future. Trial registration: The trial number was 1138 and its registration was approved by the hospital’s Research Ethics Committee in 4/2024.

1 September 2023 in Annals of Saudi Medicine
Verified
Journal Article
Open access
OMOsama Nady Mohamed Mohamed
Osama Nady Mohamed Mohamed
AMAhmed Mohamed Mady
Ahmed Mohamed Mady
MSMohamed Mamdouh Sedik
Mohamed Mamdouh Sedik
AIAhmed S. Issa
Ahmed S. Issa
OMOmima M. Mohamed
Omima M. Mohamed
NANadia Ismail Abdelhameed
Nadia Ismail Abdelhameed
BACKGROUND: The most common and lethal consequence of chronic kidney disease (CKD) is atherosclerotic cardiovascular disease. The persistent inflammation present in CKD increases hepcidin levels. Iron accumulates in the arterial wall in atherosclerosis. Hepcidin-25 was thought to accelerate the development of atherosclerotic plaques by blocking iron release from macrophages. Therefore, we sought to determine the relationship between hepcidin-25 and asymptomatic atherosclerosis in non-dialysis CKD patients.OBJECTIVES: Investigate the relationship between hepcidin-25 and subclinical atherosclerosis in non-dialysis CKD patients.DESIGN: Cross-sectionalSETTINGS: Outpatient clinic for urology and nephrology at a university hospitalSUBJECTS AND METHODS: Participants above the age of 18 years included a group of healthy controls and a group of CKD patients who were not routinely maintained on hemodialysis. The latter group was further divided according to eGFR into CKD-3, CKD-4 and CKD-5 subgroups. We excluded patients with comorbidities, patients with chronic liver disease, and other conditions or habits. CBC, kidney func-tion tests, and serum levels of hepcidin-25 (SH-25), TNF-alpha, IL-6, high -sensitivity C-reactive protein (hs-CRP), TC, TG, LDL-C and HDL-C were assessed. To measure carotid intima media thickness (CIMT) and de-termine presence of plaques, carotid ultrasonography was performed. The near or far walls of common carotid artery, bulb, and internal ca-rotid artery were used to measure CIMT.MAIN OUTCOME MEASURES: SH-25 association and indicators of subclinical atherosclerosis.SAMPLE SIZE: 128 participants, the control group (n=25) and the non-hemodialysis CKD patients (n=103)RESULTS: The CKD patients had significantly higher serum levels of markers of inflammation including IL-6, TNF-alpha, and hs-CRP (P<.001 for each) compared to the controls. There was a significantly high-er level of TC, TG and LDL-C (P<.001 for each) and a lower level of HDL-C (P<.001) in the CDK patients compared to controls. SH-25 was considerably higher in all CKD subgroups, especially with progression of CKD. CIMT was increased in CKD patients especially CKD-4 and CKD-5 subgroups when compared to healthy participants (P<.001 for each). In the patient group, CIMT showed a positive correlation with SH-25, (r=.65 and P<.001), IL-6 (r=.65, P<.001), TNF-alpha (r=.71, P<.001), and hs-CRP (r=.52, P<.001). The ROC curve study showed that SH- 25 (AUC=.86, P<.001), IL-6 (AUC=.83, P<.001), hs-CRP (AUC=.72, P<.001), TNF-alpha (AUC=.82, P<.001) were strong predictors of subclini- cal atherosclerosis in the CKD patients.CONCLUSIONS: SH-25 and CIMT had a positive relationship in CKD patients. The ROC curve showed that SH-25 is a reliable predictor of carotid atherosclerosis. Therefore, we suggest that SH-25 is a vital biomarker of asymptomatic atherosclerosis.

31 December 2024 in Journal Of Nephrology
Verified
Journal Article
Open access
PDF file
OMOsama Nady Mohamed Mohamed
Osama Nady Mohamed Mohamed
SISharehan Abdelrahman Ibrahim
Sharehan Abdelrahman Ibrahim
SEShereen Mohammed Mohammed Elsaghir
Shereen Mohammed Mohammed Elsaghir
MMMarwa Ibrahim Mohamed
Marwa Ibrahim Mohamed
BFBasma Fathy
Basma Fathy
SKShaimaa F. Kamel
Shaimaa F. Kamel
Background Studies on renal vein thrombosis have been conducted as case reports or case series. The renal outcomes and mortality risk of renal vein thrombosis have not been fully established. We aimed to investigate the clinical characteristics, treatment modalities, and predictors of renal outcomes and mortality in patients with renal vein thrombosis in a large multicenter cohort. Methods We retrospectively assessed 182 patients with renal vein thrombosis diagnosed between January 2011 and May 2023 using either Doppler ultrasonography or computed tomography venography. The main outcomes analyzed were all-cause mortality, and worsening kidney function. Results We evaluated 182 patients comprising 76 males (41.8%) and 106 females (58.2%). Nephrotic syndrome was the most common cause (51.6%) followed by malignancy (33%) and post-trauma or surgery (11%). Kidney function worsened in 126 patients (69.2%). Acute kidney injury (AKI) was identified in 72 patients (39.6%), whereas 54 patients (29.7%) developed chronic kidney disease (CKD). Multivariate logistic regression showed that declining kidney function was reliably predicted by nephrotic syndrome (Odds ratio (OR): 6.41, P = 0.004), serum albumin (OR: 0.31, P = 0.003), and diabetes mellitus (OR: 14.04, P < 0.001). Eighty-two patients (45.1%) died while being monitored. Sepsis accounted for the majority of deaths (25.3%). Bilateral renal vein thrombosis (Hazard Ratio (HR): 5.61, P < 0.001), malignancy (HR: 6.15, P = 0.004), serum albumin (HR: 0.12, P < 0.001), hemoglobin (Hb) level (HR: 0.102, P < 0.001) and diabetes mellitus (HR: 2.42, P = 0.007) were all reliable predictors of all-cause mortality using multivariate Cox regression. Conclusion Renal vein thrombosis is associated with a higher risk of mortality and worsening kidney function. It is essential to promptly identify high risk patients and start early treatment to prevent unfavorable outcomes. Graphical abstract

4 September 2025 in Kidney International Reports
Verified
Journal Article
Open access
OMOsama Nady Mohamed Mohamed
Osama Nady Mohamed Mohamed
MMMarwa Ibrahim Mohamed
Marwa Ibrahim Mohamed
SEShereen Mohammed Mohammed Elsaghir
Shereen Mohammed Mohammed Elsaghir
SAShimaa Abdelrazek
Shimaa Abdelrazek
AAAml Azzam
Aml Azzam
BFBasma Fathy
Basma Fathy
Primary focal segmental glomerulosclerosis (FSGS) is a rare, likely immune-related disease. Rituximab (RTX) may help manage it, but existing adult data are limited and mainly based on case reports or case series. We aimed to evaluate RTX treatment outcomes in a large, multicenter adult cohort. This was a retrospective study of 160 patients with primary FSGS treated with RTX as adjunctive therapy to standard immunosuppressive agents between March 2015 and June 2023, that evaluated treatment responses at 3, 6, and 12 months, followed by an extended 24-month follow-up to assess long-term outcomes. Treatment outcomes included complete response (CR), partial response (PR), or no response. Treatment-related adverse effects and relapse-free survival (RFS) were evaluated at each visit. Patients undergoing RTX retreatment and those monitored for an extended 24-month period were analyzed independently. Response rates at 3, 6, and 12 months were 57%, 71%, and 74%, respectively. Twelve-month RTX response was positively associated with lower baseline 24-hour proteinuria (odds ratio [OR] = 0.49, P = 0.043), steroid dependency (OR = 20.59, P = 0.002), and not otherwise specified (NOS) variant (OR = 234.19, P = 0.004), whereas it was negatively associated with calcineurin inhibitor (CNI) resistance (OR = 0.03, P = 0.01), treatment-related adverse effects (OR = 0.02, P = 0.003), and CD20+ B-cell repopulation at 6 months (OR = 0.08, P = 0.02). Thirty adverse effects occurred in 16 patients. Twelve-month responders had significantly longer RFS (mean: 32.8 months, 83.1% relapse-free) compared with nonresponders (median: 9 months, 16.7% relapse-free; P < 0.001). RTX retreatment was administered to 44 patients, with 2 achieving CR and 18 achieving PR. During long-term follow-up, 82 of 118 responders at 12 months maintained a sustained response, whereas 20 relapsed. Twenty-two of 42 nonresponders at 12 months had persistent disease despite RTX retreatment, whereas 10 achieved PR. RTX shows promise in treating primary FSGS, particularly in steroid-dependent patients, those with less severe nephrotic syndrome, and previous responders. RTX offers durable responses for most patients, but long-term management remains challenging in those who relapse and need retreatment.